Avisa Partners Acquires Top Intelligence Firm to Bring Comprehensive Global Investigations Offering to Clients
23.11.2022 19:28:00 EET | Business Wire | Press release
Avisa Partners today announced the acquisition and integration of Forward Risk and Intelligence LLC, a firm that conducts investigative due diligence, business intelligence research, and international risk assessments for investors, corporations, and law firms.
The announcement follows Avisa’s recent rapid expansion within the U.S. market, and the December 2021 acquisition of 35°Nord, an agency specializing in communications and influence strategies on the African continent.
The unique services provided by Forward Risk, based in Washington, D.C., complement and integrate seamlessly with Avisa’s existing advisory offerings, delivering a competitive edge for global corporations, private equity and hedge fund investors, law firms, international institutions, and high-net-worth individuals.
“Avisa Partners delivers elite advisory services to global clients working to solve complex and challenging matters,” said Eric Bovim, CEO of Avisa U.S. “With Forward Risk on board, Avisa can now expand its data-driven solutions to include investigative due diligence, strategic intelligence, and compliance.”
Forward Risk and Intelligence LLC will now be known as Forward Risk (An Avisa Partners Company) and retain its existing and independent website, branding, leadership team, and client roster. The firm’s 30 employees will integrate into Avisa’s U.S. headquarters in Washington, and its co-founders – Luke DiMaggio, Andrew Wooster, and Brendan Foo – will become partners of Avisa, with the ability to provide value-added services to all of Avisa Partners’ global clients.
“Joining Avisa Partners is a perfect fit given their scale and diverse advisory solutions that will yield immediate value for our clients,” said Forward Risk co-founder Brendan Foo. “Our best-in-class offering combined with Avisa’s global reach make this a win for all involved.”
About Forward Risk
Forward Risk (An Avisa Partners Company) is a corporate investigations, intelligence, and risk advisory firm headquartered in Washington, D.C. The firm’s experienced and resourceful team conducts investigative due diligence, business intelligence research, risk assessments, candidate vetting, and other bespoke intelligence services for asset managers, private equity, law firms, multinational corporations, and political campaigns. The firm emphasizes value-oriented results through thorough research, sophisticated analysis, clear writing, and thoughtful presentation.
About Avisa Partners
Avisa Partners is a global risk and reputation management firm that provides a comprehensive suite of advisory services to clients worldwide. Avisa’s 300 professionals, working in six cities across the globe, offer an established track-record of success working with blue-chip clients across industries, sectors, and geographies. The firm develops custom solutions to multi-stakeholder commercial, reputational, legal, regulatory, and public-perception challenges.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221117005581/en/
Contact information
Press contacts
Romain Grandjean
+33673475399
romain.grandjean@avisa-partners.com
Jean Tillinac
+33603939252
jean.tillinac@avisa-partners.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 23:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, for a total equity value of approximately $10.0 billion, or approximately $8.8 billion net of estimated cash acquired. The transaction was unanimously approved by both the Vertex and Crinetics Boards of Directors and is anticipated to close in the third quarter of 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706876183/en/ Crinetics’ marketed medicine, PALSONIFY® (paltusotine), received approval from the U.S. Food and Drug Administration (FDA) in September 2025. PALSONIFY was recently approved by the European Medicines Agency (EMA) a
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 21:30:00 EEST | Press release
The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stage name of Simone Privitera, an Italian multi-platinum DJ and producer who integrates artificial intelligence tools into a musical practice rooted in the contemporary electronic scene. With a career that has seen him collaborate wit
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 16:00:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 16:00:00 EEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
No-Loss Trading Platform UpsideOnly Surpasses 100,000 Users Within Weeks of Launch6.7.2026 15:48:00 EEST | Press release
Perpetuals.com Ltd (Nasdaq: PDC), today announced that UpsideOnly, its risk-free trading and market prediction platform, has seen a surge in new user sign-ups, surpassing the important milestone of 100,000 traders within weeks of its launch on May 19. UpsideOnly lets users make predictions about where global equity, commodity, forex, and crypto markets are heading without ever placing a real trade themselves. Perpetuals uses its own capital to trade on the strongest signals identified by its proprietary AI. If those trades win, Perpetuals shares the profits with the users who helped generate the signal. If the trade doesn’t make money, users lose nothing. Reaching 100,000 users so quickly after launching is a reflection of the enormous demand for a platform that flips the traditional retail trading model on its head, with early platform data showing strong engagement across asset classes, geographies and user activity: Users from more than 180 different countries $38.4 billion in cumul
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom